| DC Field | Value | Language |
|---|
| dc.contributor.author | Reznikov, K. M. | - |
| dc.contributor.author | Gorbunova, N. S. | - |
| dc.contributor.author | Kolesnichenko, P. D. | - |
| dc.contributor.author | Tverskoy, A. V. | - |
| dc.contributor.author | Kostina, D. A. | - |
| dc.date.accessioned | 2022-05-04T16:11:53Z | - |
| dc.date.available | 2022-05-04T16:11:53Z | - |
| dc.date.issued | 2017 | - |
| dc.identifier.citation | Search of new pharmaceuticals on the basis of darbepoetin in the treatment of ischemic stroke: review of literature / K. M. Reznikov [et al.] // Research result. Pharmacology and clinical pharmacology. - 2017. - Vol. 3, № 1.- P. 125-136. - Doi: 10.18413/2500-235X-2017-3-1-125-136. - Refer.: p. 134-136. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46594 | - |
| dc.description.abstract | The article contains the analysis of medical and biological publications from the global database created by the National Centre for Biology Information (NCBI), an intramural biotechnological division of the US National Library of Medicine. The authors have analyzed publications of the recent ten years. Major results of study of erythropoietins and their recombinant analogues have been generalized and systematized. There has been revealed the significant potential of the preparations of this group to be studied and used. Major advantages and drawbacks of erythropoietins and their recombinant analogues have been described | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | erythropoietin | ru |
| dc.subject | darbepoetin | ru |
| dc.subject | stroke | ru |
| dc.subject | review of literature | ru |
| dc.title | Search of new pharmaceuticals on the basis of darbepoetin in the treatment of ischemic stroke: review of literature | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 3, № 1
|
